Investigator
Tina Garyantes
LINNAEUS THERAPEUTICS INC · funded by NCI
- Companies
- 2
- Grants
- 2
- Non-dilutive funding
- $2.0M
- First award
- Jan 13, 2025
Resolved onto their grants.
Federal awards on file.
Summed across those awards.
On this record.
Companies from this work
Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.
- Linnaeus Therapeutics, Inc.67momentum
OncologyPhase II
- LINNAEUS THERAPEUTICS INC18momentum
OncologyGrant-only
Grant record
Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.
- R44
Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
$1000kJan 13, 2025NCILINNAEUS THERAPEUTICS INCNIH RePORTER · 11062612 (opens the source filing in a new tab)
- R44
Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
$1000kJan 13, 2025NCILINNAEUS THERAPEUTICS INCNIH RePORTER · 11258534 (opens the source filing in a new tab)
This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources